Fosun Kare, Zhongyuan Xiehe, Bangyao Biologics and more gather! CGT track schedule and highlights revealed | 2026BPD Chengdu

Chengdu's industrial foundation in the CGT sector is rapidly taking shape.Cell and gene therapy is designated as one of Chengdu's key future industries; the region's first dual US-China submission gene drug production base has commenced operations; SeedTech Incubator plans an annual capacity of 1200 batches to build a full-chain CXO platform; Ruijian Medicine secured two rounds of funding in January totaling 4.7 billion yuan, with its lead candidate NouvNeu001 granted FDA Fast Track designation and RMAT qualification; Weizhen Bio established a strategic licensing agreement with CREATE Medicines for its LNP delivery platform.The local CGT industry chain is progressively closing the gap across key stages—from R&D and pilot production to commercial-scale manufacturing.

Against this backdrop, 2026BPD Chengdu Biopharmaceutical Process Development Conferencewill be11 5-6InHyatt Place Chengdu Bio-CityGrandly hosted, bringing together2000+Professional Buyers,70+Featured speakers and a curated CGT track agenda.CGT Track Schedule and Highlights AnnouncedWe cordially invite industry professionals to join us in Chengdu to explore cutting-edge R&D, CMC advancements, and pathways for industrialization.

CGT Track Schedule and Highlights

Highlights Preview

• Topic Setup: Cutting-Edge Technology + End-to-End Coverage
  The agenda covers cutting-edge directions such as in vivo CAR-T, in vivo CAR-M, in vivo LNP delivery, rAAV, dual-plasmid processes, pluripotent stem cells, and small extracellular vesicles. It also addresses industrialization aspects including CGT manufacturing verification, quality control standards, process scale-up, and closed automated production.Establishes a complete pipeline from early-stage R&D and vector delivery to clinical translation, manufacturing quality control, and commercial scale-up—combining cutting-edge innovation with practical implementation.

• Featured Speakers: Leaders from Top Companies, Innovative Biotechs, and Regulatory Experts
  Fosun Kerry, Zhongyuan Xiehe, Bionor, ZhiShan Weixin, Xueji BioWhen gathered, the guest lineup will cover the entire CGT ecosystem, including C-level executives from leading CGT companies, founders and R&D heads of innovative Biotechs, regulatory experts, quality leaders, manufacturing leaders, and other key stakeholders—balancing industry vision with practical implementation perspectives.

CGT Track Schedule

Schedule updated through 9/19

In Vivo Delivery Strategies and Development Progress

Considerations for In Vivo CAR-T Therapy Development

Guest: Gu Haihua, Senior Vice President of R&D at Fosun Kerry

Report: Development of In Vivo LNP Delivery Systems

Guest: Gu Yongjun, Head of Formulation Research and IP at Weizhen Bio

Report: In Vivo CAR-M Development

Guest: Zhang Shaolong, R&D Director, Saiyuan Bio

Innovative CGT Therapy Development

Report: Development and Progress of rAAV Gene Therapy for Aging-Related Diseases

Guest: Dong Biao, Founder of Zhishan Weixin

Report: Pending

Guest: Saiter Biotech

Report: Progress in MSC-Based Liver Disease Therapy (Tentative)

Guest: Tan Yi, Vice President and Director of R&D at Qilu Cell Therapy

Report: Advances in Drug Research Derived from Pluripotent Stem Cells

Guest: Yan Xiang, Director of R&D, CloudTest Medicine

Report: Key Points for CGT Manufacturing Inspection

Guest: Teacher Tu, Regulatory Expert

Platform: The World's First Dual-Plasmid Gene Therapy Drug Development Platform

Guest: Chen Lijing, COO/VP of Jinweike Bio

Key Considerations for Scaling Up and Quality Control of Stem Cell Production

Report: Pending

Guest: Lin Songfeng, Blood Mist Biotech, Director of Quality

Report: Best Practices for Quality Control Standards of Clinical Extracellular Vesicles

Guest: Yang Shuangshuang, Qilu Cell Therapy, R&D Manager

Report: Closed Automated Stem Cell Production

Guest: Wu Shouliang, Deputy Director of Production Technology at Sino-Union

Youth in Action

Interview: Process Scale-Up Strategies and Quality Control Challenges for CGT Products

Guest: Tan Binghe, Bonyo Bio, CTO